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Abstract
Background: Despite the implementation of prevention guidelines, group B Streptococcal (GBS) infection remains
a leading cause of sepsis, pneumonia, and meningitis, resulting in significant neonatal morbidity and mortality.
Preventive approaches that identify women at risk of transmitting GBS have reduced the incidence of neonatal GBS
disease, and dramatically decreased the associated mortality rates. However, there is an on-going requirement for a
near-patient diagnostic test for GBS that can be carried out at the time of delivery, ideally in the labour ward
setting, particularly for women of unknown GBS colonisation status at the time of delivery.
Methods: In this study, a Recombinase Polymerase Amplification (RPA) assay was developed and performance
evaluated for the detection of group B Streptococcus in vaginal swabs. The assay uses the cAMP factor (cfb) gene of
GBS as the target gene. The analytical performance of the assay was evaluated by testing a panel of GBS reference
strains and clinical isolates, and non-GBS organisms. The limit of detection was determined and the clinical
performance was evaluated by testing 124 vaginal swabs from women with both GBS positive and negative status.
Results: Based on specificity testing carried out the assay was shown to be specific for the target of interest. The limit
of detection of the assay was shown to be between six and 12 genome copies and was comparable to that
of a real-time PCR assay, both achieving a limit of detection below 12.5 genome copies. The performance of
both assays when applied to clinical samples was identical.
Conclusion: A specific, sensitive RPA assay for GBS was developed. The performance of the assay for testing
of clinical samples is within the acceptable range.
Keywords: Group B Streptococcus, GBS, Neonatal infection, Recombinase Polymerase Amplification, Point-of-care,
Near-patient tests, Specificity, Limit of detection, Labour, Neonates
Background
Streptococcus agalactiae, or Group B Streptococcus
infection, emerged in the 1970s as the leading cause of
infectious disease in infants, and remains one of the
leading causes of neonatal sepsis and pneumonia, some-
times leading to meningitis [1]. Vertical transmission to
the infant during birth accounts for 75 % of GBS
colonisation of neonates [2], leading to either early onset
(less than 7 days) or late onset GBS disease (longer than
7 days but less than 3 months). Early onset GBS infec-
tion often presents by the twelfth hour of life and up to
89 % of cases are diagnosed in the first day of life [3]. As
a result of significant improvements in diagnosis and
disease prevention, the rate of GBS infections, both early
and late onset, has significantly reduced, and the mortal-
ity rate in neonates has dropped from 50 % to between 4
and 6 %, though for infected preterm infants it can be
significantly higher [4, 5]. GBS infection in neonates,
particularly if it leads to meningitis, can have significant
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consequences that can lead to lifelong disabling condi-
tions, including vision impairment, hearing loss and
intellectual disabilities [6].
The genital tracts of approximately 25 % of pregnant
women are colonised with GBS [7]. This colonisation
usually does not become pathogenic to the woman and
only becomes problematic in the perinatal setting. Early
onset GBS infection can be transmitted to the neonate
during birth as it travels through the birth canal of a
colonised woman and can subsequently cause infection
in the neonate [8]. In some cases it can also be transmitted
by ascending infection to the foetus if there is premature
rupture of the membranes, puerperal endometritis or if
the woman develops chorioamnionitis [8], though, these
conditions are relatively rare. It is interesting to note that
GBS was a leading cause of fatal puerperal sepsis prior to
the introduction of Penicillin [9]. Less is known about the
transmission and pathogenesis of GBS in late onset dis-
ease. In one study, 64 % of infants with late onset disease
were born to GBS positive mothers and the other 36 % are
thought to be made up of cases of environmentally
acquired GBS [10]. Intrapartum chemoprophylaxis seems
to have little effect on late onset disease attack rates.
There are two main schools of thought on the preven-
tion of invasive early onset GBS infection. Some organi-
sations, for example, The Royal College of Obstetricians
and Gynaecologists (RCOG) recommends risk-based
screening of pregnant women, while others, including
the Centres for Disease Control and Prevention (CDC)
recommend universal screening of pregnant women.
The RCOG do not recommend routine screening for the
identification of GBS, which is incidentally found when
testing for other infections such as urinary tract infec-
tion, or when testing a vaginal swab from a woman with
suspected vaginitis [3]. The current CDC guidelines for
GBS screening recommend that pregnant women have
both rectal and lower vaginal swabs screened using cul-
ture or nucleic acid testing. Typical turnaround times
for the current gold standard method for GBS detection
involving culture from swabs, are between 24 and 72 h
depending on the method employed in the laboratory
where the testing is to be done and additional time may
be required for antimicrobial susceptibility testing. The
CDC, in their 2010 GBS report, state that a rapid mo-
lecular test to determine GBS colonisation status would
be beneficial in the perinatal setting, for women with an
unknown GBS colonisation status, to reduce the likeli-
hood of invasive GBS infection of the neonate, providing
the assay is sufficiently sensitive and specific [1].
Recombinase Polymerase Amplification (RPA), a rapid,
highly sensitive and specific in vitro isothermal nucleic
acid amplification technology, offers an ideal approach
to GBS screening in near-patient settings. RPA-based
tests could be used both at the CDC recommended 35
to 37 week gestation screen as well as for screening
women who are in labour with an unknown GBS status
(e.g. women in preterm labour that have not yet been
screened or women who did not seek antenatal care).
RPA utilises a number of enzymes, including recombi-
nases and strand-displacing DNA polymerases, to per-
form DNA or RNA amplification [11]. RPA results are
generated very rapidly, typically in under 15 min, and
often in under 10, and RPA is able to detect even very
few copies of DNA [11]. A recently reported RPA assay
for GBS had a limit of detection of 20 genome copies,
with positive results available within 8 min from the
start of the reaction [12].
RPA has many features which makes it more attractive
than PCR-amplification based tests and ideal for point-of-
care NAD testing, such as are required to screen pregnant
women for GBS colonisation. It does not require thermal
cycling, with an optimum temperature range of 35–40 °C,
thus negating the need for complex instrumentation. As a
result of the extremely rapid cycling times, results are
available much more rapidly than achieved with PCR.
The objective of this study was to develop and opti-
mise an RPA-based nucleic acid diagnostic test for GBS
that can be performed in a wide variety of near-patient
clinical settings, including labour and delivery wards.
The RPA test developed in this study targets the CAMP
factor cfb gene, which is specific to GBS, and is therefore,
ideal for development of a GBS-specific assay. The analyt-
ical performance of the GBS RPA test was optimised and
the assay was evaluated using clinical samples, and com-
pared to a previously developed GBS real-time PCR assay
[13]. The results from these tests were correlated with the
results of microbiological analyses of the samples.
Methods
RPA reactions
Each RPA reaction contained 2 μl of DNA in a final re-
action volume of 50 μl. Master Mix was prepared by
adding 37.5 μl primer/probe mix (Table 1) in rehydra-
tion buffer, 9.5 μl PCR Grade H2O, 4 μl magnesium
acetate (280 mM), 2 μl template DNA per reaction at
the required concentration. For specificity testing this
concentration was 1 × 105 genome copies of DNA from
each isolate per reaction. For limit of detection experi-
ments defined copy numbers ranging from 100 to 0.78
were tested. The kit used in this study was the custom
Exo kit from TwistDx. All reagents were provided by
TwistDx. All RPA experiments were performed at 40 °C
on the Twista® instrument (TwistDx UK) device using a
reaction time of 20 min. Incubations included a manual
mixing step (5 s tube vortex) at 4 min incubation. For
negative or no template controls (NTC) these reactions
were prepared as normal substituting the target DNA
with an equal volume of molecular grade water.
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Real Time PCR reactions
A previously developed real time PCR assay for detec-
tion of GBS [13] was used to benchmark the RPA assay.
The final reaction (20 μL) contained 2 μl LC FastStart
DNA Master Hybprobe (Roche) 5 mM MgCl2, 500nM
Forward Primer, 500nM Reverse Primer, 200nM each of a
fluorescently labelled hybridisation probe pair (Tib Molbiol
Germany), 10 μL PCR grade water and 2 μL DNA, at the
required concentration. For specificity testing this concen-
tration was 1 × 105 genome copies of DNA from each
isolate. For limit of detection experiments defined copy
numbers ranging from 100 to 0.78 were tested. Thermo-
cycling conditions consisted of 95 °C for 10 mins, and
50 cycles of 95 °C for 10 s 50 °C for 15 s and 72 °C for
10 s. Reactions were carried out on the LightCycler®
Carousel-Based system (Roche).
Organisms used for inclusivity and exclusivity testing
S. agalactiae isolates used to confirm the inclusivity of
the assay are listed in Table 2. Organisms used to con-
firm exclusivity of the assay are listed in Tables 3 and 4.
DNA was extracted manually from cultures using the
Qiagen Blood and Tissue kit. DNA was quantified using
the Qubit analyser (Invitrogen). 1 × 105 genome copies
of DNA from each isolate were tested per reaction. Dilu-
tions of the target DNA for limit of detection studies
were prepared in molecular grade water.
Limit of detection of the assay
The limit of detection of the assay was determined by
preparing known concentrations of GBS (S. agalactiae
BCCM 15081) DNA and testing in the RPA assay. Eight
replicates of concentrations equivalent to 100, 50, 25,
12.5, 6.25, 3.1, 1.5 and 0.78 genome copies in a 2 μL
volume were tested in three independent experiments.
Testing of clinical samples
One hundred and twenty four vaginal swab samples
which had been stored at −20 °C in lysis buffer from the
BD GenOhm™ Lysis Kit (Beckton Dickenson USA) were
tested. This crude lysate was originally prepared by re-
suspending swabs in 1 ml of sample buffer. Of this,
400 μL was transferred into a lysis tube and lysed by
mechanical disruption with silica beads according to the
manufacturer’s instructions. From this crude lysate 2 μL
was added directly to either the RPA reaction or the
real-time PCR reaction.
Results
Analytical specificity of the RPA-GBS assay
The inclusivity of the assay was determined by testing a
panel of GBS isolates. All isolates were tested in triplicate.
Table 2 shows the results obtained, while representative
RPA amplification curve graphs are shown in Fig. 1. All
Table 1 RPA primer and probe sequences





Table 2 Organisms tested to confirm the inclusivity of the RPA
assay
Organism Source ID Result
S. agalactiae BCCM 15081 Detected
S. agalactiae BCCM 15082 Detected
S. agalactiae BCCM 15083 Detected
S. agalactiae BCCM 15084 Detected
S. agalactiae BCCM 15085 Detected
S. agalactiae BCCM 15086 Detected
S. agalactiae BCCM 15087 Detected
S. agalactiae BCCM 15090 Detected
S. agalactiae BCCM 15094 Detected
S. agalactiae BCCM 15095 Detected
S. agalactiae ATCC 13813 Detected
S. agalactiae ATCC 12386 Detected
S. agalactiae ATCC 27591 Detected
S. agalactiae ATCC 12973 Detected
S. agalactiae ATCC 31475 Detected
S. agalactiae ATCC 12403 Detected
S. agalactiae ATCC BAA-611D Detected
BCCM Belgian Coordinated Collections of Microorganisms
ATCC American Tissue Culture Collection
Table 3 Streptococcus genus panel used in exclusivity tests for
the RPA GBS assay
Organism Source ID Result
Streptococcus anginosus DSMZ 20563 Not Detected
Streptococcus dysgalactiae subsp. equisimilis DSMZ 6176 Not Detected
Streptococcus gordonii DSMZ 6777 Not Detected
Streptococcus intermedius DSMZ 20573 Not Detected
Streptococcus mitis DSMZ 12643 Not Detected
Streptococcus mutans DSMZ 20523 Not Detected
Streptococcus oralis DSMZ 20627 Not Detected
Streptococcus parasanguinis DSMZ 6778 Not Detected
Streptococcus pneumoniae DSMZ 11865 Not Detected
Streptococcus pneumoniae DSMZ 11866 Not Detected
Streptococcus pyogenes DSMZ 20565 Not Detected
Streptococcus salivarius DSMZ 20560 Not Detected
DSMZ German collection of microorganisms and cell culture
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GBS strains tested were detected. A positive signal
(change in fluorescence over background) is detected
automatically by the Twista software. The specificity of
the assay was further challenged by testing a panel of
closely related Streptococcus species. No cross-reaction
was observed (Table 3, Fig. 2a, b & c). Finally a panel
of organisms associated with the site of infection were
tested in duplicate. No cross-reactivity was observed
(Additional file 1).
Limit of detection
The limit of detection (LoD) of the RPA and real-time
PCR assays was determined by testing eight replicates of
each of the following concentrations, 100, 50, 25, 12.5,
6.25, 3.1, 1.5 and 0.8 genome copies of GBS
BCCM15081 in three independent runs. Table 4 shows
the hit rate analysis for the combined data from three
independent experiments. The LoD of the RPA GBS
assay was shown to be between 6.25 and 12.5 genome
equivalents, while the LoD of the real-time PCR GBS
assay was shown to be in the range of 3.1 and 6.25 gen-
ome copies, indicating that the analytical sensitivity of
both assays is comparable.
Clinical performance evaluation
One hundred and twenty four samples were tested in
the RPA-GBS assay. For comparison the same sample
set was also tested in the real-time PCR assay. All samples
had previously been cultured for GBS. Figure 3 shows rep-
resentative RPA amplification curves obtained for some of
the clinical samples tested. Eighty five samples were posi-
tive when tested by RPA and 39 samples were negative
(Additional file 2). The same result was obtained when the
samples were re-tested using real-time PCR (Additional
file 2). The results were in full agreement with the pre-
determined culture status of the samples.
Table 4 Hit rate analysis for the GBS RPA and real-time PCR assays showing number of replicates of each target input concentration
detected
Target input genome copies No replicates tested No replicates detected in RPA assay No replicates detected in PCR assay
100 24 24 24
50 24 24 24
25 24 24 24
12.5 24 24 24
6.25 24 20 24
3.1 24 15 14
1.5 24 14 18
0.8 24 10 9
a b
Fig. 1 RPA Amplification curves obtained from a panel of GBS isolates tested with the RPA GBS assay. All isolates, listed in Table 1, were tested in
triplicate. a shows amplification curves obtained for isolates BCCM 15081, 15082, and BCCM15083. b shows amplification curves obtained for
isolates BCCM 15083, 15084, and BCCM15085 (tested in duplicate)
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Discussion
The aim of this study was to demonstrate the application
of RPA, a rapid amplification technology and its utility
for detection of GBS in clinical samples. The current
gold standard for determination of GBS status involves
swab culture for 48 h in selective media [1]. The RPA assay
described in this study can be completed in 10–15 min
post sample processing and offers a viable alternative for
rapid near patient testing.
The gene target used for development of the RPA-GBS
assay was the cfb gene. This gene is present in all GBS
isolates [14] and considering the sequence homegeniety
among isolates is a good target for development of an
inclusive molecular test. Following an extensive in-silico
analysis of cfb gene sequences primers and probes for
the RPA-GBS assay were designed according the criteria
required for RPA amplification (www.twistdx.co.uk).
An extensive performance evaluation of the assay was
carried out with respect to analytical specificity and sen-
sitivity. The inclusivity of the assay was determined by
testing 17 GBS isolates, all of which were detected. The
exclusivity of the assay was determined by testing a
panel of 12 organisms from the Streptococcus genus.
None of these related organisms gave a signal in the
assay. The exclusivity of the assay was further challenged
by testing a panel of 78 unrelated organisms commonly
found in the gastrointestinal and genital tracts. None of
these organisms produced a signal, demonstrating the
specificity of the RPA-GBS assay.
The limit of detection (analytical sensitivity) of the
assay was determined by testing replicates of varying
concentrations of GBS DNA. This was done over three
independent experiments. Hit rate analysis showed the
limit of detection to be between six and 12 genome
copies.
The performance of the RPA assay was compared to a
previously published real-time PCR [13]. The limit of
detection of the real-time PCR assay was comparable to
that of the RPA assay, with both achieving a limit of de-
tection below 12.5 genome copies., The performance of
both assays when applied to clinical samples was identi-
cal. Some clinical samples which presumably had low
cell counts also gave late onset times (late fluorescence
signals) in RPA assays and CP values in PCR assays (data
not shown) but were none the less detected, indicating
that the limit of detection is in the acceptable range for
application to clinical samples.
From the results presented here, the potential of RPA
as a technology for use in a point of care (POC) or near
patient setting is clear. Furthermore, the RPA reagents
can be lyophilised and because the reaction is isothermal,
instrumentation requirements are relatively straightfor-
ward. The reaction time is within the 10–15 min range,
which offers the significant advantage of fast turnaround
time compared to many other amplification technologies.
These characteristics of RPA technology mean that it
would be ideally suited for the development of POC as-
says. Detection of GBS during labour is one application
particularly suited to a point of care setting. Results are
often required rapidly and the current gold standard cul-
ture method takes 48 h to turn around meaning that it is
cannot be used in a labour ward setting. Even in relation
to other standard molecular tests such as real-time PCR
the results obtained with RPA are very promising.
In order to further optimise the RPA assay described
here for full clinical validation, some additional develop-
ment work would be required including optimisation of
a b c
Fig. 2 RPA results obtained when a Streptococcus Genus exclusivity panel, listed in Table 2, was tested in the RPA GBS assay. a, b and c show
amplification curves for only for the positive control GBS 15081, demonstrating specificity of the assay for GBS
Fig. 3 Representative RPA amplification curves obtained for eight of
the 124 clinical samples tested in the RPA GBS assay
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an appropriate sample preparation method, compatible
with the RPA reaction, and the addition of either a
process control or internal amplification control (IAC)
to the assay as a target. IACs used in RPA assays have
been previously reported [12].
Conclusion
We report here the evaluation of a specific, sensitive and
rapid RPA assay for GBS detection in clinical samples.
The newly developed assay is specific for the target of
interest and has a limit of detection between six and 12
genome copies. The assay was compared to a previously
published real-time PCR assay for GBS. When applied
to testing of clinical samples the performance of the
RPA assay was identical to the real-time PCR assay with
the added advantage that the assay time was reduced
significantly to between 10 and 15 min. The newly de-
scribed RPA assay could potentially be utilised in a near-
patient testing setting, allowing rapid clinical decisions
to be made on the necessity to administer appropriate
antibiotic treatment.
Additional files
Additional file 1: Non-streptococcal species found at the site of
infection used in RPA assay exclusivity testing. (DOCX 22 kb)
Additional file 2: Clinical sample analysis results. (DOCX 24 kb)
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